Dr. ArgilÃ©s on BRAF-Mutations in Colorectal Cancer
Guillem Argilés, MD, department of Medical Oncology, Vall d’Hebron University Hospital, discusses the benefits of molecular subtyping in colorectal cancer.
Identifying new subtypes in colorectal cancer has made a significant impact on treatment options for colorectal cancer, Argilés says.
By identifying and targeting BRAF-mutations, patients with a previously poor prognosis are experiencing improved survival outcomes and response rates.
Additional subtyping and targeted therapies for those molecular subtypes is key to combating colorectal cancer, says Argilés.